



(51) International Patent Classification:

A61K 31/381 (2006.01) A61K 31/4965 (2006.01)
A61K 31/44 (2006.01) A61K 31/5375 (2006.01)
A61K 31/4409 (2006.01) A61K 31/55 (2006.01)
A61K 31/445 (2006.01) A61P 35/00 (2006.01)
A61K 31/4462 (2006.01)

(21) International Application Number:

PCT/EP2024/081665

(22) International Filing Date:

08 November 2024 (08.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23209032.4 10 November 2023 (10.11.2023) EP

(71) Applicants: UNIVERSITÄT DUISBURG-ESSEN [DE/DE]; Universitätsstr. 2, 45141 Essen (DE). TECHNISCHE UNIVERSITÄT DORTMUND [DE/DE]; August-Schmidt-Str. 4, 44227 Dortmund (DE). MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG

DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstr. 8, 80539 München (DE).

(72) Inventors: BAUER, Sebastian; c/o Labor für Translationale Sarkomforschung (AG Bauer), Innere Klinik (Tumorforschung), Hufelandstr. 55, 45122 Essen (DE). MÜHLENBERG, Thomas; Buschkante 3, 45472 Mülheim an der Ruhr (DE). RAUH, Daniel; Ludwig-Uhland-Str. 1, 67549 Worms (DE). SIEVERS, Sonja; c/o Max-Planck-Institut für molekulare Physiologie, Otto-Hahn-Str. 11, 44227 Dortmund (DE). TEUBER, Alina; Düsseldorfer Str. 45, 44143 Dortmund (DE). SCHULZ, Tom; Frohlinger Str. 79, 44379 Dortmund (DE). WARMUTH, Jonas; Erich-Grisar-Weg 14 C, 45699 Herten (DE). LATEGHAN, Jonas; Bovermannstr. 24, 44141 Dortmund (DE).

(74) Agent: MAIWALD GMBH; Grünstraße 25, 40212 Düsseldorf (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

(54) Title: COMPOUNDS FOR USE IN THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR (GIST)

Driver	Cell line	Imatinib	Sunitinib	Regorafenib	Ripretinib	Avapritinib	AZD7762
KIT	T1-AYdup (e9)	115	4	164	84	88	27
	GIST-T1 (e11)	18	9	34	8	20	2
	GIST430 (e11)	11	4	23	4	27	1
	GIST882 (e13)	103	26	211	99	330	21
	T1-AY-V654A (e9+13)	>1000	21	566	106	534	30
	T1-V654A (e11+13)	747	15	314	71	77	1
	GIST430/654 (e11+13)	>1000	47	527	120	217	6
	T1-T6701 (e11+14)	>1000	28	106	714	349	4
	T1-C809G (e11+17)	310	56	104	11	30	1
	T1-D816A (e11+17)	346	>1000	218	16	57	3
	T1-D816E (e11+17)	445	>1000	172	11	37	1
	T1-D820A (e11+17)	642	>1000	440	8	18	2
	T1-D820Y (e11+17)	97	160	116	7	14	1
	T1-AY-N822K (e9+17)	931	>1000	157	16	185	7
	T1-N822K (e11+17)	>1000	>1000	366	22	14	1
	T1-A829P (e11+18)	>1000	>1000	437	26	84	6
	T1-V654A-829 (e11+13+18)	>1000	82	>1000	>1000	46	1
	T1-V654A-816A (e11+13+17)	>1000	825	>1000	>1000	119	7
	T1-V654A-822 (e11+13+17)	>1000	194	>1000	>1000	75	2
PDGFRA	T1-a-D842V (e18)	>1000	>1000	673	1046	20	9
	T1-a-D842V+G690R (e18+18)	>1000	>1000	>1000	>1000	>1000	241
	T1-a-N659K (e14)	176	123	127	58	300	30
	T1-a-N659K-T674R (e14+15)	>1000	>1000	406	197	>1000	39
GIST48B (KIT-negative)		>1000	>1000	>1000	>1000	>1000	194

Figure 3

(57) Abstract: The present invention relates to method of treating a patient suffering from a gastrointestinal stromal tumor (GIST), comprising administering to said patient a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Furthermore, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a gastrointestinal stromal tumor (GIST) in a patient.

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))